Drugs / Cofact
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT02074358 | Feb → Apr 2014 | — | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05205863 | Nov 2021 → Aug 2022 | — | Prothya Biosolutions | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-12-08 | Bristol-Myers Squibb | Results Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects bms.com ↗
The study results demonstrated that both PCCs, Sanquin’s Cofact (a heparin-free formulation) and CSL Behring’s Beriplex P/N (a formulation containing heparin) reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential (ETP). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-12-08 | Bristol-Myers Squibb | Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects bms.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cofact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02074358 ↗ |
| Modality | Protein / enzyme biologic | “Cofact (4-Factor PCC)” NCT02074358 ↗ |
| Route | Intravenous | “a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously” NCT02074358 ↗ |